Technical Analysis for XNCR - Xencor, Inc.

Grade Last Price % Change Price Change
F 37.29 0.13% 0.05
XNCR closed up 0.13 percent on Friday, June 11, 2021, on 1.9 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical XNCR trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.22%
Inside Day Range Contraction 1.22%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.43%
Inside Day Range Contraction 0.43%
Oversold Stochastic Weakness 0.43%
Stochastic Buy Signal Bullish -0.82%
Older End-of-Day Signals for XNCR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 3 days ago
Possible NR7 3 days ago
Down 1% 3 days ago
10 DMA Resistance 3 days ago
Rose Above 10 DMA 4 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xencor, Inc. Description

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Immunology Immune System Antibodies Autoimmune Diseases Monoclonal Antibodies Autoimmune Disease Antibody Rheumatoid Arthritis Asthma Glycoproteins Lupus Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Boehringer Ingelheim Antibody Product Catalent Immunoglobulin E Manufacturing Services Agreement

Is XNCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.33
52 Week Low 29.28
Average Volume 184,579
200-Day Moving Average 42.51
50-Day Moving Average 40.50
20-Day Moving Average 38.56
10-Day Moving Average 37.36
Average True Range 1.57
ADX 18.0
+DI 12.72
-DI 18.47
Chandelier Exit (Long, 3 ATRs) 36.61
Chandelier Exit (Short, 3 ATRs) 40.61
Upper Bollinger Bands 41.44
Lower Bollinger Band 35.68
Percent B (%b) 0.28
BandWidth 14.95
MACD Line -1.08
MACD Signal Line -1.08
MACD Histogram 0.0042
Fundamentals Value
Market Cap 2.14 Billion
Num Shares 57.5 Million
EPS 0.61
Price-to-Earnings (P/E) Ratio 61.43
Price-to-Sales 28.14
Price-to-Book 4.17
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.67
Resistance 3 (R3) 38.62 38.12 38.44
Resistance 2 (R2) 38.12 37.77 38.14 38.36
Resistance 1 (R1) 37.70 37.55 37.91 37.75 38.29
Pivot Point 37.20 37.20 37.30 37.22 37.20
Support 1 (S1) 36.78 36.85 36.99 36.83 36.29
Support 2 (S2) 36.28 36.63 36.30 36.22
Support 3 (S3) 35.86 36.28 36.14
Support 4 (S4) 35.91